On 20 Dec 2021, IHL announced they had completed dosing the OSA patients.
Joel Latham made these comments.
“Based on the results of a confidential interim analysis of the data from this trial performed in July, we submitted a patent application regarding the methods for the treatments of OSA. The key claims in the application were deemed novel and inventive by the International Search Report and Opinion, thus strengthening our intellectual property around IHL-42X.”
And also.
“Our preparation for a pre-IND meeting with the FDA demonstrates our commitment to advancing IHL42X into a larger, pivotal phase 2 clinical trial under an IND application. We expect the pre-IND meeting to occur in the first quarter of 2022,”
IMO that sounds like a positive sign. And what is an OSA drug worth to IHL in a US$10 billion per annum OSA market? There are currently no pharmacotherapy options in this space.
As always, stick to the fundamentals that got us to this point and be careful about the noise.
IHL Price at posting:
56.0¢ Sentiment: Buy Disclosure: Held
